Markets

Merck’s Phase 3 KEYNOTE-C93 Trial Meets Primary Endpoint Of Progression-Free Survival, Reducing Risk Of Progression Or Death By 43% With KEYTRUDA Monotherapy vs. Platinum Doublet Chemotherapy In dMMR Advanced Or Recurrent Endometrial Cancer

Oct 26, 2026 · 11:36 AM ET· updated 1h ago

KEYNOTE-C93 showed median progression-free survival (PFS) was more than four times longer for these patients treated with KEYTRUDA as monotherapy (38.2 months) compared to platinum doublet chemotherapy (8.4

Why It Matters

Merck's cancer medicine KEYTRUDA worked better than older treatments. Patients stayed healthier longer, which shows the drug is strong medicine.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

MRK141.11

-4.16 (-2.86%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.